XML 49 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2018
Fair Value Disclosures [Abstract]  
Summary of Asset and Liability Fair Values
The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among three fair value measurement categories (see Note 2(xiii)):
 
June 30, 2018
Fair Value Measurements
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Assets:

 

 

 

 
Bank certificates of deposits
$

 
$
249

 
$

 
$
249

 
Money market funds

 
163,602

 

 
163,602

 
Equity securities (Note 3(a))
95,038

 

 

 
95,038

 
Mutual funds

 
101

 

 
101

 
Deferred compensation investments (life insurance cash surrender value - Note 3(g))

 
6,123

 

 
6,123

*

$
95,038

 
$
170,075

 
$

 
$
265,113

 
Liabilities:

 

 

 

 
Deferred executive compensation liability (Note 15(f))
$

 
$
5,973

 
$

 
$
5,973

*
Drug development liability (Note 14)

 

 
12,191

 
12,191

 
Talon CVR (Note 9(a))

 

 
6,693

 
6,693

 
Corixa Liability (Note 15(b)(i))

 

 
62

 
62

 
 
$

 
$
5,973

 
$
18,946

 
$
24,919

 
 
 
December 31, 2017
Fair Value Measurements
 
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Assets:

 

 

 

 
Bank certificates of deposits
$

 
$
248

 
$

 
$
248

 
Money market funds

 
216,358

 

 
216,358

 
Equity securities (Note 10)
37,530

 

 

 
37,530

 
Mutual funds

 
59

 

 
59

 
Deferred compensation investments (life insurance cash surrender value)

 
14,887

 

 
14,887

*

$
37,530

 
$
231,552

 
$

 
$
269,082

 
Liabilities:

 

 

 

 
Deferred executive compensation liability (Note 15(f))
$

 
$
11,038

 
$

 
$
11,038

*
Drug development liability (Note 14)

 

 
12,386

 
12,386

 
Talon CVR (Note 9(a))

 

 
6,210

 
6,210

 
Corixa Liability (Note 15(b)(i))

 

 
62

 
62

 

$

 
$
11,038

 
$
18,658

 
$
29,696

 

* The reported amount of “deferred compensation investments” is based on the cash surrender value of (ex)employee life insurance policies at period-end, while the reported amount of “deferred executive compensation liability” is based on the period-end market value of investments selected by plan participants.
Fair Value Measurement Activity for Liabilities Utilize Level 3 Inputs
The table below summarizes the 2017 and 2018 activity of our liabilities that are valued with unobservable inputs:
 
Fair Value Measurements of
Unobservable Inputs (Level 3)
Balance as of December 31, 2016
$
14,445

FOLOTYN development liability (see Note 14)
(744
)
Talon CVR fair value adjustment - MARQIBO (see Note 9(a))
4,957

Balance as of December 31, 2017
18,658

FOLOTYN development liability (see Note 14)
(195
)
Talon CVR fair value adjustment - MARQIBO (see Note 9(a))
483

Balance as of June 30, 2018
$
18,946

* This amount is comprised of the current and non-current portions of “FOLOTYN development liability” and the non-current portion of “acquisition-related contingent obligations” on our accompanying Condensed Consolidated Balance Sheets.